Novo Nordisk's Wegovy pill ad debuts during the Golden Globes

Novo Nordisk launched its first direct-to-consumer television ad for the Wegovy pill during the Golden Globes telecast on 11 January 2026, part of a campaign called "Live lighter" ^[1]. Less than four weeks later, the US Food and Drug Administration wrote to the company saying the ad was "false or misleading" and overstated what the drug has been shown to do ^[1][2].

The Wegovy pill is an oral form of semaglutide and, according to the BMJ's account, the first oral GLP-1 drug to reach the market ^[1]. The ad opens with the line "Meet Wegovy pill, the first and only FDA-approved GLP-1 weight loss pill," then shows people rollerblading, riding bikes and going on amusement rides while a narrator says, "Weight loss has never looked like this. Now you can live lighter by losing weight" ^[2].

What the FDA objected to

The agency's letter, dated 5 February, is an Untitled Letter — a step the FDA uses for advertising it considers violative ^[2]. FDA officials singled out two phrases from the voiceover: "Now you can live lighter by losing weight" and "It's a way forward." Those statements, the letter said, "misleadingly imply additional weight loss compared with other currently approved GLP-1 treatments, when this has not been demonstrated" ^[1].

The FDA also said the ad's claims suggest the pill offers "superior efficacy and/or safety" over approved GLP-1 injections without data to back that up, and that the presentation "misleadingly imply that Wegovy in pill form uniquely enables patients to achieve outcomes that were not previously possible with other GLP-1 treatments for weight loss" ^[2].

A second line of criticism was about emotion. The FDA said the ad implies benefits beyond physical weight loss — "emotional relief, reduced psychological burden, hope, or direction for patients'" lives — and positions the drug as a "solution to broader life challenges" rather than a treatment for weight loss ^[1][2]. Separately, the agency said the ad fails to present the major statement — the required rundown of risks — at the same time in both audio and on-screen text ^[2].

Novo's response, and the Super Bowl ad

Liz Skrbkova, Novo Nordisk's head of US media and stakeholder relations, confirmed the company received the letter and said the ad in question had been running since launch — it was not the company's Super Bowl ad ^[2]. "Novo Nordisk is committed to responsible advertising that is accurate, balanced and meets all FDA regulatory and compliance standards," she said, adding that the company takes regulatory feedback seriously and is responding to the FDA's concerns ^[2]. "We believe in Wegovy and it is our hope that patients who can benefit from it are aware of it and encouraged to have an informed discussion with their healthcare professional" ^[2].

The letter arrived shortly after Novo Nordisk ran its first Super Bowl ad for the Wegovy pill, featuring Kenan Thompson, DJ Khaled and Danielle Brooks joking about problems a pill might solve, such as parallel parking ^[2]. Whether the FDA will raise similar objections to that spot is not yet known; the agency had not sent letters or commented on any Super Bowl ads as of the report ^[2].

Why it matters for patients

The practical takeaway is narrow but useful: a federal regulator has said on the record that this ad's suggestion of extra weight loss versus other GLP-1 options is not supported by evidence ^[1][2]. That gap between advertising language and demonstrated results is the kind of thing worth raising with a clinician rather than settling from a commercial.

The sources do not report how much weight the Wegovy pill produced in trials, how it compares head-to-head with semaglutide or tirzepatide injections, what it costs, or whether insurers cover it. Those details are not in this coverage.

What happens next

Novo Nordisk said it is in the process of responding to the FDA ^[2]. The sources do not give a deadline for that response or say whether the ad has been pulled or revised. The BMJ report on the letter was published 14 February 2026 ^[1].